MacroGenics, Inc. (MGNX)
USD 1.75
(4.17%)
USD 1.75
(4.17%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 217.21 Million USD | -21.37% |
| 2022 | 265.97 Million USD | -3.56% |
| 2021 | 275.78 Million USD | 20.52% |
| 2020 | 228.82 Million USD | -4.34% |
| 2019 | 239.2 Million USD | 3.41% |
| 2018 | 231.32 Million USD | 30.21% |
| 2017 | 177.65 Million USD | 21.17% |
| 2016 | 146.62 Million USD | 21.14% |
| 2015 | 121.03 Million USD | 41.43% |
| 2014 | 85.57 Million USD | 51.77% |
| 2013 | 56.38 Million USD | 9.62% |
| 2012 | 51.44 Million USD | 23.05% |
| 2011 | 41.8 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q3 | 56.34 Million USD | -15.07% |
| 2024 Q2 | 64.34 Million USD | 9.25% |
| 2024 Q1 | 58.89 Million USD | 1.53% |
| 2023 Q2 | 56.92 Million USD | -3.71% |
| 2023 Q4 | 58.01 Million USD | 26.62% |
| 2023 FY | 209.12 Million USD | -21.37% |
| 2023 Q3 | 45.81 Million USD | -19.51% |
| 2023 Q1 | 59.11 Million USD | 2.99% |
| 2022 Q3 | 63.54 Million USD | -2.85% |
| 2022 Q4 | 57.4 Million USD | -9.67% |
| 2022 Q2 | 65.41 Million USD | -15.34% |
| 2022 FY | 265.97 Million USD | -3.56% |
| 2022 Q1 | 77.26 Million USD | 8.95% |
| 2021 FY | 275.78 Million USD | 20.52% |
| 2021 Q4 | 70.91 Million USD | 6.0% |
| 2021 Q3 | 66.89 Million USD | -5.28% |
| 2021 Q2 | 70.62 Million USD | 4.87% |
| 2021 Q1 | 67.34 Million USD | 24.91% |
| 2020 Q1 | 58.41 Million USD | -7.59% |
| 2020 FY | 228.82 Million USD | -4.34% |
| 2020 Q3 | 53.55 Million USD | -14.93% |
| 2020 Q4 | 53.91 Million USD | 0.68% |
| 2020 Q2 | 62.94 Million USD | 7.76% |
| 2019 FY | 239.2 Million USD | 3.41% |
| 2019 Q2 | 62.95 Million USD | 10.23% |
| 2019 Q3 | 55.92 Million USD | -11.16% |
| 2019 Q4 | 63.21 Million USD | 13.02% |
| 2019 Q1 | 57.11 Million USD | -1.75% |
| 2018 Q3 | 55.62 Million USD | -11.52% |
| 2018 Q1 | 54.71 Million USD | 10.89% |
| 2018 FY | 231.32 Million USD | 30.21% |
| 2018 Q4 | 58.12 Million USD | 4.51% |
| 2018 Q2 | 62.86 Million USD | 14.91% |
| 2017 FY | 177.65 Million USD | 21.17% |
| 2017 Q2 | 42.26 Million USD | 7.03% |
| 2017 Q1 | 39.48 Million USD | -11.69% |
| 2017 Q3 | 48.8 Million USD | 15.48% |
| 2017 Q4 | 49.33 Million USD | 1.1% |
| 2016 Q2 | 38.4 Million USD | 18.07% |
| 2016 Q1 | 32.52 Million USD | -14.38% |
| 2016 FY | 146.62 Million USD | 21.14% |
| 2016 Q4 | 44.71 Million USD | 23.25% |
| 2016 Q3 | 36.27 Million USD | -5.53% |
| 2015 FY | 121.03 Million USD | 41.43% |
| 2015 Q1 | 26.03 Million USD | 6.71% |
| 2015 Q3 | 30.12 Million USD | 12.04% |
| 2015 Q4 | 37.99 Million USD | 26.12% |
| 2015 Q2 | 26.88 Million USD | 3.28% |
| 2014 FY | 85.57 Million USD | 51.77% |
| 2014 Q4 | 24.39 Million USD | 9.84% |
| 2014 Q3 | 22.21 Million USD | 3.49% |
| 2014 Q2 | 21.46 Million USD | 22.57% |
| 2014 Q1 | 17.5 Million USD | -2.41% |
| 2013 Q1 | 13.39 Million USD | 15.32% |
| 2013 Q3 | 12.95 Million USD | 7.13% |
| 2013 Q4 | 17.94 Million USD | 38.51% |
| 2013 FY | 56.38 Million USD | 9.62% |
| 2013 Q2 | 12.09 Million USD | -9.75% |
| 2012 FY | 51.44 Million USD | 23.05% |
| 2012 Q4 | 11.61 Million USD | -10.17% |
| 2012 Q3 | 12.93 Million USD | 0.0% |
| 2011 FY | 41.8 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Absci Corporation | 73.66 Million USD | -194.865% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | 32.491% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 87.933% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -2085.779% |
| Apollomics, Inc. | 54.14 Million USD | -301.21% |
| 180 Life Sciences Corp. | 13.47 Million USD | -1511.686% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -592.275% |
| Bicycle Therapeutics plc | 216.92 Million USD | -0.135% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -156.404% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -26.36% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -362.101% |
| Chimerix, Inc. | 93.38 Million USD | -132.592% |
| CRISPR Therapeutics AG | 463.49 Million USD | 53.135% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -544.02% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -86.526% |
| Fortress Biotech, Inc. | 200.19 Million USD | -8.502% |
| Fortress Biotech, Inc. | 200.19 Million USD | -8.502% |
| Gritstone bio, Inc. | 148.37 Million USD | -46.397% |
| Allakos Inc. | 196.05 Million USD | -10.792% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -296.407% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -52.471% |
| Cytokinetics, Incorporated | 173.61 Million USD | -25.115% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -739.154% |
| Innoviva, Inc. | 132.15 Million USD | -64.365% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -2723.819% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1739.704% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -70.952% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -1684520.754% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -111.797% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -144.43% |
| ImmuCell Corporation | 9.61 Million USD | -2158.572% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -37.64% |
| Incyte Corporation | 1.19 Billion USD | 81.754% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -63.868% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3128.172% |
| Mustang Bio, Inc. | 48.5 Million USD | -347.857% |
| MiMedx Group, Inc. | 229.72 Million USD | 5.446% |
| MEI Pharma, Inc. | 34.78 Million USD | -524.45% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -2359.622% |
| Mereo BioPharma Group plc | 35.84 Million USD | -506.035% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -1114.0% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -35.303% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -26.398% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -840.789% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -1267.336% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -2011.959% |
| NextCure, Inc. | 67.63 Million USD | -221.148% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -301.655% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -633.686% |
| Onconetix, Inc. | 34.9 Million USD | -522.26% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -1604.182% |
| Opthea Limited | 191.96 Million USD | -13.152% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -264.008% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -7794.177% |
| PDS Biotechnology Corporation | 43.04 Million USD | -404.62% |
| Precigen, Inc. | 84.18 Million USD | -158.033% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -199.334% |
| Prime Medicine, Inc. | 186.63 Million USD | -16.382% |
| PureTech Health plc | 144.59 Million USD | -50.221% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | 16.346% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 92.284% |
| Replimune Group, Inc. | 234.77 Million USD | 7.479% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2409.223% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -66.751% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -1018.597% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | 56.449% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -793.646% |
| Sesen Bio, Inc. | 78.38 Million USD | -177.127% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | 5.014% |
| Solid Biosciences Inc. | 104.31 Million USD | -108.23% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | 5.54% |
| SciSparc Ltd. | 9.01 Million USD | -2310.554% |
| Sutro Biopharma, Inc. | 243 Million USD | 10.614% |
| TG Therapeutics, Inc. | 198.47 Million USD | -9.442% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -78.915% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -2811.339% |
| Travere Therapeutics, Inc. | 472 Million USD | 53.98% |
| UroGen Pharma Ltd. | 138.88 Million USD | -56.396% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -207.696% |
| XOMA Corporation | 46.46 Million USD | -367.501% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | 13.992% |
| AbCellera Biologics Inc. | 275.23 Million USD | 21.079% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -282.697% |
| Cassava Sciences, Inc. | 105.95 Million USD | -105.003% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -1461.615% |
| Precision BioSciences, Inc. | 92.46 Million USD | -134.921% |
| Dyadic International, Inc. | 9.15 Million USD | -2273.235% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -2511.071% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -876.116% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -631.807% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -65.569% |
| IGM Biosciences, Inc. | 265.59 Million USD | 18.214% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -102.019% |
| Acelyrin, Inc. | 422.06 Million USD | 48.535% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -1110.853% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -157.599% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -3126.631% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | 11.342% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -605.908% |
| Senti Biosciences, Inc. | 94.7 Million USD | -129.36% |
| Mesoblast Limited | 5.9 Million USD | -3580.363% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | 11.022% |
| ChromaDex Corporation | 56.37 Million USD | -285.276% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -551.709% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -8.005% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -2601.039% |
| Seer, Inc. | 110.49 Million USD | -96.592% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -28.96% |
| Novavax, Inc. | 779.12 Million USD | 72.121% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -1284.436% |
| Fate Therapeutics, Inc. | 254.04 Million USD | 14.497% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -315.715% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | 12.108% |
| Celcuity Inc. | 66.23 Million USD | -227.969% |
| ContextLogic Inc. | 387 Million USD | 43.872% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -29.428% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -563.333% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 93.328% |
| Amarin Corporation plc | 272.35 Million USD | 20.246% |
| AnaptysBio, Inc. | 181.56 Million USD | -19.633% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -652.182% |
| Aptorum Group Limited | 10.56 Thousand USD | -2055692.164% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -95.924% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | 51.268% |
| Ardelyx, Inc. | 169.93 Million USD | -27.821% |
| Celularity Inc. | 215.05 Million USD | -1.003% |
| Omeros Corporation | 94.75 Million USD | -129.248% |
| Humacyte, Inc. | 23.49 Million USD | -824.437% |
| Immunocore Holdings plc | 308.04 Million USD | 29.485% |
| IO Biotech, Inc. | 91.44 Million USD | -137.541% |
| GT Biopharma, Inc. | 13.57 Million USD | -1499.993% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -190.939% |
| Summit Therapeutics Inc. | 87.68 Million USD | -147.719% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -637.097% |
| Pulmatrix, Inc. | 22.03 Million USD | -885.638% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | 60.618% |
| Evogene Ltd. | 27.79 Million USD | -681.63% |
| CorMedix Inc. | 48.95 Million USD | -343.678% |
| BioLineRx Ltd. | 50.8 Million USD | -327.572% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -537.274% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -563.454% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 83.442% |
| scPharmaceuticals Inc. | 65.17 Million USD | -233.264% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -91.431% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | 41.072% |
| NLS Pharmaceutics AG | 11.8 Million USD | -1739.704% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -793.646% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -25.652% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -480.665% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -744.932% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -75.807% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -161.538% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -308.865% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -2469.76% |
| Daré Bioscience, Inc. | 33.6 Million USD | -546.292% |
| bluebird bio, Inc. | 240.23 Million USD | 9.581% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 87.561% |
| DBV Technologies S.A. | 92.16 Million USD | -135.693% |
| Avidity Biosciences, Inc. | 245.15 Million USD | 11.398% |
| Galecto, Inc. | 35.62 Million USD | -509.692% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -486.054% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -249.884% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | 1.19% |
| GlycoMimetics, Inc. | 39.28 Million USD | -452.917% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | 26.547% |
| ADMA Biologics, Inc. | 66.58 Million USD | -226.217% |
| Clene Inc. | 41.07 Million USD | -428.851% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | 38.3% |
| Aptose Biosciences Inc. | 52.35 Million USD | -314.881% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -1407.352% |
| Soligenix, Inc. | 7.79 Million USD | -2686.504% |
| Century Therapeutics, Inc. | 56.07 Million USD | -287.393% |
| Kura Oncology, Inc. | 165.8 Million USD | -31.007% |
| Surrozen, Inc. | 18.55 Million USD | -1070.97% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -89.696% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -8652.885% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -101.689% |
| Autolus Therapeutics plc | 196.72 Million USD | -10.415% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -156.582% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -1020.647% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -44.294% |
| GRI Bio, Inc. | 11.33 Million USD | -1817.167% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -2978.574% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -167.962% |
| INmune Bio, Inc. | 29.89 Million USD | -626.569% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -25.882% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -438.804% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1259.347% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -2538.044% |
| Jaguar Health, Inc. | 42.01 Million USD | -416.994% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -1279.883% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -249.794% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -563.961% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | 21.211% |
| Coherus BioSciences, Inc. | 301.45 Million USD | 27.944% |
| Verastem, Inc. | 92.08 Million USD | -135.888% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -16.955% |
| Histogen Inc. | 14.27 Million USD | -1421.966% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -1253.521% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | 71.195% |
| Surrozen, Inc. | 18.55 Million USD | -1070.97% |
| Organovo Holdings, Inc. | 14.91 Million USD | -1356.353% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4167.287% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -2745.794% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -21.938% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -348.347% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -1313.555% |
| Kronos Bio, Inc. | 128.11 Million USD | -69.543% |
| Turnstone Biologics Corp. | 78.33 Million USD | -177.279% |
| Synaptogenix, Inc. | 8.31 Million USD | -2512.687% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -1389.202% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -64.339% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | 14.163% |
| Exelixis, Inc. | 1.58 Billion USD | 86.311% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | 6.393% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | 74.601% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -215.44% |
| ESSA Pharma Inc. | 32.13 Million USD | -575.964% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -1227.702% |
| Avid Bioservices, Inc. | 25.99 Million USD | -735.571% |
| Insmed Incorporated | 949.26 Million USD | 77.117% |
| MediWound Ltd. | 18.86 Million USD | -1051.235% |
| OmniAb, Inc. | 83.89 Million USD | -158.913% |
| Alector, Inc. | 248.8 Million USD | 12.696% |
| Seres Therapeutics, Inc. | 234.3 Million USD | 7.295% |
| Zai Lab Limited | 547.47 Million USD | 60.324% |
| AlloVir, Inc. | 180.93 Million USD | -20.053% |
| Revance Therapeutics, Inc. | 398.65 Million USD | 45.513% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -96.078% |
| Aura Biosciences, Inc. | 84.99 Million USD | -155.574% |
| Immunic, Inc. | 99.22 Million USD | -118.916% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -36.603% |
| Veracyte, Inc. | 357.93 Million USD | 39.314% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 97.591% |
| FibroGen, Inc. | 398.11 Million USD | 45.439% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1428.607% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | 16.271% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -3053.552% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -2948.318% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -739.543% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | 31.379% |
| Fortrea Holdings Inc. | 457.3 Million USD | 52.501% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -300.19% |
| XBiotech Inc. | 37.51 Million USD | -479.086% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -215.44% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -28.319% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -473.596% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -951.94% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -52.903% |
| Agenus Inc. | 78.18 Million USD | -177.829% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -119.243% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -96.191% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | 77.332% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -653.042% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | 49.56% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -873.695% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -35.94% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -3827.265% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -753.195% |
| Lantern Pharma Inc. | 17.87 Million USD | -1115.014% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -405.151% |
| Ainos, Inc. | 12.95 Million USD | -1576.991% |
| Pluri Inc. | 22.48 Million USD | -866.259% |
| Prothena Corporation plc | 282.4 Million USD | 23.084% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -8.596% |
| Rallybio Corporation | 78.93 Million USD | -175.193% |
| Kodiak Sciences Inc. | 277.32 Million USD | 21.674% |
| Cue Biopharma, Inc. | 19.54 Million USD | -1011.529% |
| MeiraGTx Holdings plc | 151.07 Million USD | -43.777% |
| Annexon, Inc. | 143.72 Million USD | -51.134% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -848.164% |
| Moderna, Inc. | 6.39 Billion USD | 96.603% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -6307.522% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -150.06% |
| Blueprint Medicines Corporation | 722.86 Million USD | 69.951% |
| Immix Biopharma, Inc. | 16.14 Million USD | -1245.725% |
| CalciMedica, Inc. | 21.81 Million USD | -895.623% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -51.569% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -26.808% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -19.809% |
| Sana Biotechnology, Inc. | 294.94 Million USD | 26.353% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -528.243% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -199.396% |
| Nutriband Inc. | 5.73 Million USD | -3688.173% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -398.051% |
| Vor Biopharma Inc. | 126.03 Million USD | -72.344% |
| Roivant Sciences Ltd. | 1.18 Billion USD | 81.734% |
| Alkermes plc | 996.24 Million USD | 78.197% |
| ProKidney Corp. | 151.52 Million USD | -43.355% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -192.841% |
| Arcellx, Inc. | 200.19 Million USD | -8.5% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | 64.636% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -44.137% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -470.537% |
| Atai Life Sciences N.V. | 125.78 Million USD | -72.688% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -166.067% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -166.819% |
| MediciNova, Inc. | 10.9 Million USD | -1892.75% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -68.619% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2892.138% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3506.921% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | 54.401% |
| Biomea Fusion, Inc. | 126.13 Million USD | -72.208% |
| RenovoRx, Inc. | 11.39 Million USD | -1806.064% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -13.672% |
| Geron Corporation | 70.44 Million USD | -208.364% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -687.524% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -62.598% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | 10.302% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | 17.109% |
| Royalty Pharma plc | 862.4 Million USD | 74.813% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -4.433% |
| Imunon, Inc. | 20.31 Million USD | -969.475% |
| BioAtla, Inc. | 129.68 Million USD | -67.492% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -155.794% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -420.176% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -4.525% |
| Structure Therapeutics Inc. | 102.77 Million USD | -111.35% |
| 89bio, Inc. | 151.2 Million USD | -43.657% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -95.388% |
| aTyr Pharma, Inc. | 12.97 Million USD | -1573.588% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -109.554% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | 14.739% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -2540.972% |
| Akari Therapeutics, Plc | 16.8 Million USD | -1192.485% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -9452.237% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | 27.43% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -25.653% |
| Liquidia Corporation | 87.98 Million USD | -146.88% |
| Entera Bio Ltd. | 8.86 Million USD | -2351.637% |
| GH Research PLC | 41.22 Million USD | -426.939% |
| Vericel Corporation | 142.04 Million USD | -52.925% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -863.516% |
| Xencor, Inc. | 306.97 Million USD | 29.241% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -4302.763% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -1259.347% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -960.108% |
| Vaxcyte, Inc. | 468.04 Million USD | 53.591% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -366.707% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -13.253% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -3128.172% |
| Portage Biotech Inc. | 18.19 Million USD | -1093.555% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -2892.138% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -106.948% |
| OncoCyte Corporation | 25.63 Million USD | -747.272% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -3463.468% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -1795.905% |
| Purple Biotech Ltd. | -22.46 Million USD | 1066.818% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -644.984% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -603.895% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | 13.968% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -1218.052% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -633.067% |
| United Therapeutics Corporation | 885.1 Million USD | 75.459% |
| HilleVax, Inc. | 133.34 Million USD | -62.897% |
| Silo Pharma, Inc. | 3.92 Million USD | -5438.577% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -5410.207% |
| Pharming Group N.V. | 225.49 Million USD | 3.67% |
| Tharimmune, Inc. | 9.45 Million USD | -2197.302% |
| Genprex, Inc. | 31.06 Million USD | -599.327% |
| Apogee Therapeutics, Inc. | 93 Million USD | -133.557% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -15.832% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -164.265% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -28294.118% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -3887.851% |
| OKYO Pharma Limited | 8243.57 USD | -2634862.765% |
| Savara Inc. | 15.74 Million USD | -1279.581% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -1144.286% |
| Curis, Inc. | 58.35 Million USD | -272.23% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -4165.4% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -703.845% |
| BeiGene, Ltd. | 3.28 Billion USD | 93.391% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -41.368% |
| Erasca, Inc. | 141.52 Million USD | -53.482% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4698.238% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -4698.238% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -409.787% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -1412.008% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -225.655% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -400.334% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -4.365% |
| Adicet Bio, Inc. | 152.03 Million USD | -42.869% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | 49.207% |
| Aditxt, Inc. | 25.95 Million USD | -737.027% |
| Adagene Inc. | 41.83 Million USD | -419.264% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2871.438% |
| Quantum-Si incorporated | 111.65 Million USD | -94.534% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -1390.043% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -506.373% |
| Compugen Ltd. | 43.97 Million USD | -393.996% |
| Generation Bio Co. | 144.46 Million USD | -50.356% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -161.61% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -151.232% |
| Invivyd, Inc. | 205.75 Million USD | -5.57% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -201.023% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -2216.094% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -188.642% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -2011.549% |
| 2seventy bio, Inc. | 289.88 Million USD | 25.069% |
| Instil Bio, Inc. | 85.78 Million USD | -153.209% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -1595.947% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -19044.97% |
| GeoVax Labs, Inc. | 6.02 Million USD | -3506.921% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -491.351% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -109.461% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -27.565% |
| Vir Biotechnology, Inc. | 767.72 Million USD | 71.706% |
| Evaxion Biotech A/S | 22.27 Million USD | -875.37% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -60.254% |
| Verve Therapeutics, Inc. | 234.88 Million USD | 7.522% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -171.706% |
| Cingulate Inc. | 22.75 Million USD | -854.406% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 2999.293% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -386.299% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -249.929% |
| Clearmind Medicine Inc. | 8.74 Million USD | -2384.914% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -158.368% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7305.936% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -115.433% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | 42.913% |
| ImmunityBio, Inc. | 362.87 Million USD | 40.14% |
| Korro Bio, Inc. | 84.53 Million USD | -156.956% |
| Kineta, Inc. | 21.15 Million USD | -926.73% |
| BioVie Inc. | 31.95 Million USD | -579.855% |
| Codexis, Inc. | 66.51 Million USD | -226.551% |
| Celularity Inc. | 215.05 Million USD | -1.003% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -1234.572% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | 4.151% |
| Virax Biolabs Group Limited | 6.54 Million USD | -3217.747% |
| Cibus, Inc. | 320.3 Million USD | 32.185% |
| IN8bio, Inc. | 30.33 Million USD | -616.007% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -70.243% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -33839.844% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | 72.137% |
| Eyenovia, Inc. | 25.4 Million USD | -754.96% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -54.805% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3805.34% |
| Elevation Oncology, Inc. | 45.44 Million USD | -377.973% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -174.494% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -373.235% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -0.372% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -2081.531% |
| Moolec Science SA | 52.75 Million USD | -311.777% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -255.286% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -366.728% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -130.903% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -348.115% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -2228.668% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -859.916% |
| Humacyte, Inc. | 23.49 Million USD | -824.437% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -171.071% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -1393.913% |
| Genelux Corporation | 24.33 Million USD | -792.603% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -540.318% |
| Notable Labs, Ltd. | 14.77 Million USD | -1370.65% |
| Immunovant, Inc. | 282.7 Million USD | 23.167% |
| Quantum-Si incorporated | 111.65 Million USD | -94.534% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -921.371% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -112.931% |
| Acasti Pharma Inc. | 11.3 Million USD | -1822.087% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -847.664% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -424.877% |
| PepGen Inc. | 84.76 Million USD | -156.253% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -848.661% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -563.748% |
| Immuneering Corporation | 58.41 Million USD | -271.861% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -4167.287% |
| Belite Bio, Inc | 31.66 Million USD | -585.913% |
| XOMA Corporation | 46.46 Million USD | -367.501% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -221.562% |
| Bionomics Limited | 17.89 Billion USD | 98.786% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 708.786% |
| uniQure N.V. | 285.08 Million USD | 23.807% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -2871.438% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -11.847% |
| Forte Biosciences, Inc. | 32.47 Million USD | -568.827% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -2514.291% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -638.952% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -3805.34% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -1428.607% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -2343.638% |
| Altimmune, Inc. | 30.55 Million USD | -610.875% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -207.222% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 708.786% |
| Peak Bio, Inc. | 1249.13 USD | -17389202.955% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -193.059% |
| Benitec Biopharma Inc. | 22.38 Million USD | -870.49% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | 10.681% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -661.01% |
| Zura Bio Limited | 62.63 Million USD | -246.778% |
| PolyPid Ltd. | 21.04 Million USD | -932.145% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -661.01% |
| argenx SE | 1.53 Billion USD | 85.836% |
| Immunome, Inc. | 122.82 Million USD | -76.856% |
| Verona Pharma plc | 67.15 Million USD | -223.471% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -739.154% |
| Shattuck Labs, Inc. | 93.61 Million USD | -132.033% |
| CervoMed Inc. | 14.95 Million USD | -1352.189% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -2442.31% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -325.912% |
| Moolec Science SA | 52.75 Million USD | -311.777% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -1220.581% |
| Design Therapeutics, Inc. | 78.19 Million USD | -177.804% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -149.555% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -1625.983% |
| Achilles Therapeutics plc | 75.25 Million USD | -188.639% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -7305.936% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -290.302% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -326.925% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -228.621% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -301.335% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -378.352% |
| Beam Therapeutics Inc. | 554.19 Million USD | 60.805% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | 12.586% |
| AEON Biopharma, Inc. | 48.42 Million USD | -348.523% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -132.37% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -160.047% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -1625.723% |
| NeurAxis, Inc. | 8.82 Million USD | -2362.42% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | 51.836% |
| Lumos Pharma, Inc. | 38.66 Million USD | -461.787% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -719.604% |
| Palisade Bio, Inc. | 13.32 Million USD | -1530.743% |
| Nutriband Inc. | 5.73 Million USD | -3688.173% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -147.144% |
| Neurogene Inc. | 55.58 Million USD | -290.794% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -2470.288% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -124.604% |
| Athira Pharma, Inc. | 125.46 Million USD | -73.127% |
| HCW Biologics Inc. | 21.02 Million USD | -933.003% |
| XOMA Corporation | 46.46 Million USD | -367.501% |
| Nektar Therapeutics | 190.9 Million USD | -13.783% |
| Arvinas, Inc. | 480 Million USD | 54.747% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -9452.237% |
| Merus N.V. | 200.49 Million USD | -8.34% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -110.164% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -527.426% |
| Rezolute, Inc. | 70.38 Million USD | -208.601% |
| Clene Inc. | 41.07 Million USD | -428.851% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -1226.222% |
| BeyondSpring Inc. | 24.86 Million USD | -773.577% |
| Synlogic, Inc. | 58.53 Million USD | -271.105% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -1114.034% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -4735.597% |
| Peak Bio, Inc. | 1249.13 USD | -17389202.955% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -259.354% |
| Krystal Biotech, Inc. | 160.42 Million USD | -35.399% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | 19.738% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | 37.589% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -9971.478% |
| MannKind Corporation | 125.59 Million USD | -72.946% |
| Ikena Oncology, Inc. | 84.57 Million USD | -156.825% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -2151.633% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -142.425% |
| Gossamer Bio, Inc. | 183.75 Million USD | -18.206% |
| CohBar, Inc. | 12.38 Million USD | -1653.389% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -328.229% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -687.524% |
| Legend Biotech Corporation | 583.14 Million USD | 62.751% |
| Mural Oncology plc | 192.07 Million USD | -13.091% |
| Disc Medicine, Inc. | 91.12 Million USD | -138.37% |
| Champions Oncology, Inc. | 28.11 Million USD | -672.732% |
| REGENXBIO Inc. | 321.15 Million USD | 32.365% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -3951.586% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -289.581% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -457.524% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -89.945% |
| Vaxart, Inc. | 90.72 Million USD | -139.419% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -2449.469% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -407.582% |
| Cellectis S.A. | 97.32 Million USD | -123.197% |
| Longeveron Inc. | 21.25 Million USD | -922.188% |
| Repare Therapeutics Inc. | 167.35 Million USD | -29.791% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 84.038% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -187.151% |
| Revolution Medicines, Inc. | 498.76 Million USD | 56.449% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -3165.409% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -394.187% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -191.212% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -211.934% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -1863.969% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 95.451% |
| Denali Therapeutics Inc. | 527.23 Million USD | 58.801% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -2409.223% |
| Veru Inc. | 101.34 Million USD | -114.326% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -827.992% |
| Cingulate Inc. | 22.75 Million USD | -854.406% |
| Passage Bio, Inc. | 108.38 Million USD | -100.403% |
| Context Therapeutics Inc. | 25.07 Million USD | -766.344% |
| Exicure, Inc. | 14.07 Million USD | -1443.159% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -5.411% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -401.64% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -2266.875% |
| Nuvalent, Inc. | 149.49 Million USD | -45.302% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -2592.669% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -109.566% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -912.705% |
| OmniAb, Inc. | 83.89 Million USD | -158.913% |
| Anew Medical, Inc. | 1.3 Million USD | -16598.044% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -562.969% |
| Lipocine Inc. | 15.08 Million USD | -1340.404% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -217.042% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -185.239% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -438.804% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -89.141% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -870.403% |
| Sage Therapeutics, Inc. | 664.14 Million USD | 67.294% |
| Ocugen, Inc. | 71.56 Million USD | -203.513% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -131.41% |
| Q32 Bio Inc. | 92.68 Million USD | -134.371% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -925.857% |
| Alumis Inc. Common Stock | 158.17 Million USD | -37.327% |
| Equillium, Inc. | 50.6 Million USD | -329.228% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -248.067% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -1462.074% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -1051.411% |
| Dominari Holdings Inc. | 23.83 Million USD | -811.328% |
| Edesa Biotech, Inc. | 9.22 Million USD | -2255.207% |
| vTv Therapeutics Inc. | 11.9 Million USD | -1724.263% |
| Bio-Techne Corporation | 563.03 Million USD | 61.421% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | 46.866% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | 19.178% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -64.212% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -1407.286% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -32.694% |
| Nkarta, Inc. | 131.65 Million USD | -64.994% |
| BioCardia, Inc. | 12.12 Million USD | -1692.055% |
| Iterum Therapeutics plc | 47.46 Million USD | -357.603% |